Diffuse Intrinsic Pontine Glioma Clinical Trial
— AflacST1501Official title:
Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors
Verified date | October 2023 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase I clinical trial evaluating abemaciclib (LY2835219), an inhibitor of cyclin dependent-kinases 4 and 6 (Cdk 4/6) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) and in relapsed/refractory/progressive malignant brain (Grade III/IV, including DIPG; MBT) and solid tumor (ST) patients (Stratum B).
Status | Completed |
Enrollment | 53 |
Est. completion date | October 10, 2023 |
Est. primary completion date | October 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 25 Years |
Eligibility | Inclusion Criteria for All Participants: - Patient must have measurable or evaluable disease. - Age must be = 2 years and < 25 years - Body surface area (BSA) = 0.5 m^2 - Lansky (for participants = 16 years) or Karnofsky (for participants > 16 years) performance score = 40 at the time of study enrollment - Adequate organ function at the time of study enrollment as follows: - Bone marrow: Absolute neutrophil count (ANC) = 1,000/µL, platelet count = 75,000/µL (transfusion independent for = 7 days), hemoglobin concentration = 8g/dL (may be transfused) - Patients with bone marrow metastatic disease who do not meet the above criteria will be eligible to enroll in the study with the following count criteria. These patients will not be evaluable for hematologic toxicity or hematologic DLT. - ANC > 750/µL within 7 days prior to first dose of abemaciclib - Platelet count > 50,000/µL (may receive platelet transfusions) within 7 days prior to first dose of abemaciclib - Hemoglobin = 7.5 g/dL (may receive red blood cell (RBC) transfusions) within 7 days prior to first dose of abemaciclib - Renal: Normal serum creatinine concentration based on age or glomerular filtration rate (GFR) > 70 ml/min/1.73m^2 - Hepatic: Total bilirubin concentration < 1.5x the institutional upper limit of normal for age; serum glutamic pyruvic transaminase (SGPT) < 10x the institutional upper limit of normal for patients on Stratum A. Stratum B patients must have SGPT < 4x the institutional upper limit of normal. - Cardiac: Adequate cardiac conductivity with corrected Q-T interval (QTC) of < 450 ms on screening ECG. - Female research participants of childbearing age must not be pregnant as confirmed by a serum or urine pregnancy test within 1 week of start of treatment. Participants must not be breast-feeding. - All patients should submit an archival tumor biopsy specimen (collected at diagnosis or relapse). Patients who have no tumor tissue available may be permitted to participate after discussion with the principal investigator. - Males or females of reproductive potential may not participate unless they have agreed to use two effective contraceptive methods. Abstinence in a non-sexually active child will be sufficient birth control. Inclusion Criteria for Stratum A (Newly Diagnosed DIPG) - Diagnosis of DIPG or high-grade glioma originating from the brainstem - Participants have had no previous treatment except corticosteroid use. Inclusion Criteria for Stratum B (Recurrent/refractory/progressive MBT (including DIPG) or ST) - Stratum B is closed to further accrual of participants - Patients must have radiologic evidence of recurrent, refractory or progressive malignant central nervous system (WHO Grade III or IV) or solid tumor. For patients with radiologic features of DIPG histologic confirmation of diagnosis is not required though biopsy is suggested if clinically indicated. - Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration. - Patients who are on dexamethasone must be on a stable or decreasing dose for at least one week prior to registration. - Patients must have fully recovered from the acute toxic effects of chemotherapy, immunotherapy, or radiotherapy prior to entering this study. - Myelosuppressive chemotherapy: Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least 21 days prior to study registration or at least six weeks if nitrosourea. At least two weeks must have lapsed if patients received lower dose oral etoposide (50 mg/2) without experiencing evidence of myelosuppression (i.e. neutropenia or requiring transfusion with blood products) - Biologic agent: Patient must have recovered from any toxicity potentially related to the agent and received their last dose of the biologic agent = 7 days prior to study registration. - Monoclonal antibody treatment: At least three half-lives must have elapsed prior to registration. - Radiation: Patient has received radiation therapy prior to study registration. Patients must have had their last fraction of local irradiation to the primary tumor = 3 months prior to registration, their last fraction of craniospinal irradiation (>24Gy) or total body irradiation > 3 months prior to registration or > 6 wks for therapeutic doses of metaiodobenzylguanidine (MIBG). Patient has not received focal irradiation for symptomatic metastatic sites within 14 days prior to registration. - Bone Marrow Transplant: Patient must be = 3 months since high dose chemotherapy and peripheral blood stem cell rescue prior to registration. - Autologous stem cell transplant following myeloablative therapy within 3 months prior to the first dose of abemaciclib or prior allogeneic stem cell transplant at any time. Patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria. - Growth factors: Patients must be off all colony forming growth factors(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long-acting formulations (e.g. Neulasta). Exclusion Criteria: - Patients with uncontrolled infection - Patients with any concomitant significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy, or that would impair the evaluation of side effects related to this treatment, alter drug metabolism or the tolerance to this treatment - Patients receiving any other anticancer or investigational drug therapy - Prior therapy with abemaciclib - Known mutation of Rb in tumor tissue - Prior history of QTC prolongation or QTC>450 ms on screening ECG. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Healthcare of Atlanta, Egleston | Atlanta | Georgia |
United States | Children's Healthcare of Atlanta, Scottish Rite | Atlanta | Georgia |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Phoenix Children's Hospital | Phoenix | Arizona |
Lead Sponsor | Collaborator |
---|---|
Emory University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Abemaciclib Maximum Tolerated Dose (MTD) for Diffuse Intrinsic Pontine Glioma (DIPG) | The maximum dose of abemaciclib tolerated in participants with newly diagnosed diffuse intrinsic pontine glioma (DIPG). | Week 6 | |
Primary | Abemaciclib Maximum Tolerated Dose (MTD) for Recurrent/Refractory Solid Tumors | The maximum dose of abemaciclib in participants with recurrent/refractory solid tumors, including malignant tumors of the brain and spine. | Week 6 | |
Primary | Pharmacokinetics (PK): Predose Concentration (Cmin) of Abemaciclib | Cycle 1 to End of Study (up to two years) | ||
Primary | Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib | Cycle 1 to End of Study (up to two years) | ||
Primary | Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Abemaciclib | Cycle 1 to End of Study (up to two years) | ||
Secondary | Number of participants with adverse events | The number of participants who experience adverse events. | End of study (Up to two years) | |
Secondary | Number of hematological toxicities | The number of hematological toxicities observed throughout the study among participants. | End of study (Up to two years) | |
Secondary | Number of non-hematological toxicities | The number of non-hematological toxicities observed throughout the study among participants. | End of study (Up to two years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
Recruiting |
NCT05476939 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
|
Phase 3 | |
Terminated |
NCT03330197 -
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
|
Phase 1/Phase 2 | |
Terminated |
NCT03690869 -
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02992015 -
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
|
Early Phase 1 | |
Terminated |
NCT01182350 -
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
|
Phase 2 | |
Recruiting |
NCT04837547 -
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04911621 -
Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06333899 -
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
|
Early Phase 1 | |
Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
Active, not recruiting |
NCT02420613 -
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
|
Phase 1 | |
Completed |
NCT03086616 -
CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)
|
Phase 1 | |
Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06093165 -
RE-irradiation of Diffuse MIdline Glioma paTients
|
N/A | |
Withdrawn |
NCT03632317 -
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
|
Phase 2 | |
Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
Recruiting |
NCT02233049 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
|
Phase 2 | |
Completed |
NCT00996723 -
Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
|
Phase 1 | |
Recruiting |
NCT05009992 -
Combination Therapy for the Treatment of Diffuse Midline Gliomas
|
Phase 2 | |
Recruiting |
NCT04049669 -
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
|
Phase 2 |